ID   USP9X_HUMAN             Reviewed;        2570 AA.
AC   Q93008; O75550; Q8WWT3; Q8WX12;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   12-APR-2017, entry version 177.
DE   RecName: Full=Probable ubiquitin carboxyl-terminal hydrolase FAF-X;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme FAF-X;
DE   AltName: Full=Fat facets in mammals;
DE            Short=hFAM;
DE   AltName: Full=Fat facets protein-related, X-linked;
DE   AltName: Full=Ubiquitin thioesterase FAF-X;
DE   AltName: Full=Ubiquitin-specific protease 9, X chromosome;
DE   AltName: Full=Ubiquitin-specific-processing protease FAF-X;
GN   Name=USP9X; Synonyms=DFFRX, FAM, USP9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Fetal brain, Retina, and Testis;
RX   PubMed=8922996; DOI=10.1093/hmg/5.11.1695;
RA   Jones M.H., Furlong R.A., Burkin H., Chalmers I.J., Brown G.M.,
RA   Khwaja O., Affara N.A.;
RT   "The Drosophila developmental gene fat facets has a human homologue in
RT   Xp11.4 which escapes X-inactivation and has related sequences on
RT   Yq11.2.";
RL   Hum. Mol. Genet. 5:1695-1701(1996).
RN   [2]
RP   ERRATUM.
RA   Jones M.H., Furlong R.A., Burkin H., Chalmers I.J., Brown G.M.,
RA   Khwaja O., Affara N.A.;
RL   Hum. Mol. Genet. 6:334-335(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2226-2570 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-2556, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH BIRC5.
RX   PubMed=16322459; DOI=10.1126/science.1120160;
RA   Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y.;
RT   "Chromosome alignment and segregation regulated by ubiquitination of
RT   survivin.";
RL   Science 310:1499-1504(2005).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1600, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2563, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2443, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17693683; DOI=10.1074/mcp.M700120-MCP200;
RA   Tang L.-Y., Deng N., Wang L.-S., Dai J., Wang Z.-L., Jiang X.-S.,
RA   Li S.-J., Li L., Sheng Q.-H., Wu D.-Q., Li L., Zeng R.;
RT   "Quantitative phosphoproteome profiling of Wnt3a-mediated signaling
RT   network: indicating the involvement of ribonucleoside-diphosphate
RT   reductase M2 subunit phosphorylation at residue serine 20 in canonical
RT   Wnt signal transduction.";
RL   Mol. Cell. Proteomics 6:1952-1967(2007).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH MARK4 AND NUAK1.
RX   PubMed=18254724; DOI=10.1042/BJ20080067;
RA   Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M.,
RA   Alessi D.R.;
RT   "Control of AMPK-related kinases by USP9X and atypical
RT   Lys(29)/Lys(33)-linked polyubiquitin chains.";
RL   Biochem. J. 411:249-260(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1600, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1600; SER-2443 AND
RP   SER-2563, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   FUNCTION, INTERACTION WITH SMAD4, AND SUBCELLULAR LOCATION.
RX   PubMed=19135894; DOI=10.1016/j.cell.2008.10.051;
RA   Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L.,
RA   Adorno M., Martello G., Stinchfield M.J., Soligo S., Morsut L.,
RA   Inui M., Moro S., Modena N., Argenton F., Newfeld S.J., Piccolo S.;
RT   "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling,
RT   controls Smad4 monoubiquitination.";
RL   Cell 136:123-135(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1600, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2563 AND THR-2567, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1600 AND SER-2443, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588; THR-590; SER-1600;
RP   SER-2443 AND SER-2563, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   FUNCTION, INTERACTION WITH DCX, SUBCELLULAR LOCATION, VARIANTS MRX99
RP   HIS-2093 AND ILE-2157, AND CHARACTERIZATION OF VARIANTS MRX99 HIS-2093
RP   AND ILE-2157.
RX   PubMed=24607389; DOI=10.1016/j.ajhg.2014.02.004;
RA   Homan C.C., Kumar R., Nguyen L.S., Haan E., Raymond F.L., Abidi F.,
RA   Raynaud M., Schwartz C.E., Wood S.A., Gecz J., Jolly L.A.;
RT   "Mutations in USP9X are associated with X-linked intellectual
RT   disability and disrupt neuronal cell migration and growth.";
RL   Am. J. Hum. Genet. 94:470-478(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Deubiquitinase involved both in the processing of
CC       ubiquitin precursors and of ubiquitinated proteins. May therefore
CC       play an important regulatory role at the level of protein turnover
CC       by preventing degradation of proteins through the removal of
CC       conjugated ubiquitin. Essential component of TGF-beta/BMP
CC       signaling cascade. Regulates chromosome alignment and segregation
CC       in mitosis by regulating the localization of BIRC5/survivin to
CC       mitotic centromeres. Specifically hydrolyzes both 'Lys-29'- and
CC       'Lys-33'-linked polyubiquitins chains. Specifically
CC       deubiquitinates monoubiquitinated SMAD4, opposing the activity of
CC       E3 ubiquitin-protein ligase TRIM33. Involved in axonal growth and
CC       neuronal cell migration. {ECO:0000269|PubMed:16322459,
CC       ECO:0000269|PubMed:18254724, ECO:0000269|PubMed:19135894,
CC       ECO:0000269|PubMed:24607389}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC   -!- SUBUNIT: Interacts with SMAD4, MARK4, NUAK1 and BIRC5/survivin.
CC       Interacts with DCX. {ECO:0000269|PubMed:16322459,
CC       ECO:0000269|PubMed:18254724, ECO:0000269|PubMed:19135894,
CC       ECO:0000269|PubMed:24607389}.
CC   -!- INTERACTION:
CC       P42858:HTT; NbExp=8; IntAct=EBI-302524, EBI-466029;
CC       Q13485:SMAD4; NbExp=2; IntAct=EBI-302524, EBI-347263;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19135894}.
CC       Cell projection, growth cone {ECO:0000269|PubMed:24607389}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=Q93008-3; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=Q93008-1; Sequence=VSP_040478;
CC   -!- TISSUE SPECIFICITY: Widely expressed in embryonic and adult
CC       tissues.
CC   -!- DISEASE: Mental retardation, X-linked 99 (MRX99) [MIM:300919]: A
CC       disorder characterized by significantly below average general
CC       intellectual functioning associated with impairments in adaptive
CC       behavior and manifested during the developmental period.
CC       Intellectual deficiency is the only primary symptom of non-
CC       syndromic X-linked mental retardation, while syndromic mental
CC       retardation presents with associated physical, neurological and/or
CC       psychiatric manifestations. {ECO:0000269|PubMed:24607389}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Escapes X-inactivation.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD13527.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAD18900.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98296; CAA66942.1; -; mRNA.
DR   EMBL; AL391259; CAD13527.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL109797; CAD13527.2; JOINED; Genomic_DNA.
DR   EMBL; AL109797; CAD18900.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL391259; CAD18900.2; JOINED; Genomic_DNA.
DR   EMBL; AF070645; AAC25395.1; -; mRNA.
DR   CCDS; CCDS43930.1; -. [Q93008-3]
DR   CCDS; CCDS55403.1; -. [Q93008-1]
DR   RefSeq; NP_001034679.2; NM_001039590.2. [Q93008-3]
DR   RefSeq; NP_001034680.2; NM_001039591.2. [Q93008-1]
DR   UniGene; Hs.77578; -.
DR   ProteinModelPortal; Q93008; -.
DR   BioGrid; 113867; 139.
DR   DIP; DIP-27562N; -.
DR   IntAct; Q93008; 33.
DR   MINT; MINT-5006529; -.
DR   STRING; 9606.ENSP00000316357; -.
DR   BindingDB; Q93008; -.
DR   ChEMBL; CHEMBL2406899; -.
DR   MEROPS; C19.017; -.
DR   iPTMnet; Q93008; -.
DR   PhosphoSitePlus; Q93008; -.
DR   BioMuta; USP9X; -.
DR   DMDM; 317373496; -.
DR   EPD; Q93008; -.
DR   MaxQB; Q93008; -.
DR   PaxDb; Q93008; -.
DR   PeptideAtlas; Q93008; -.
DR   PRIDE; Q93008; -.
DR   Ensembl; ENST00000324545; ENSP00000316357; ENSG00000124486. [Q93008-3]
DR   Ensembl; ENST00000378308; ENSP00000367558; ENSG00000124486. [Q93008-1]
DR   GeneID; 8239; -.
DR   KEGG; hsa:8239; -.
DR   UCSC; uc004dfb.3; human. [Q93008-3]
DR   CTD; 8239; -.
DR   DisGeNET; 8239; -.
DR   GeneCards; USP9X; -.
DR   HGNC; HGNC:12632; USP9X.
DR   HPA; CAB011618; -.
DR   HPA; CAB070164; -.
DR   HPA; HPA047417; -.
DR   MalaCards; USP9X; -.
DR   MIM; 300072; gene.
DR   MIM; 300919; phenotype.
DR   neXtProt; NX_Q93008; -.
DR   OpenTargets; ENSG00000124486; -.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA37257; -.
DR   eggNOG; KOG1866; Eukaryota.
DR   eggNOG; COG5077; LUCA.
DR   GeneTree; ENSGT00760000119158; -.
DR   HOGENOM; HOG000231283; -.
DR   HOVERGEN; HBG073749; -.
DR   InParanoid; Q93008; -.
DR   KO; K11840; -.
DR   OMA; QLWLCAD; -.
DR   OrthoDB; EOG091G0069; -.
DR   PhylomeDB; Q93008; -.
DR   TreeFam; TF323966; -.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SIGNOR; Q93008; -.
DR   ChiTaRS; USP9X; human.
DR   GeneWiki; USP9X; -.
DR   GenomeRNAi; 8239; -.
DR   PRO; PR:Q93008; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000124486; -.
DR   CleanEx; HS_USP9X; -.
DR   ExpressionAtlas; Q93008; baseline and differential.
DR   Genevisible; Q93008; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030426; C:growth cone; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; TAS:Reactome.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0048675; P:axon extension; IMP:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0007059; P:chromosome segregation; IEA:UniProtKB-KW.
DR   GO; GO:0007292; P:female gamete generation; TAS:ProtInc.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0001764; P:neuron migration; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00443; UCH; 1.
DR   SUPFAM; SSF48371; SSF48371; 5.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell cycle; Cell division; Cell projection;
KW   Chromosome partition; Complete proteome; Cytoplasm; Disease mutation;
KW   Hydrolase; Mental retardation; Mitosis; Phosphoprotein; Protease;
KW   Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN         1   2570       Probable ubiquitin carboxyl-terminal
FT                                hydrolase FAF-X.
FT                                /FTId=PRO_0000080689.
FT   DOMAIN     1557   1956       USP.
FT   ACT_SITE   1566   1566       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   ACT_SITE   1879   1879       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   MOD_RES     588    588       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     590    590       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1600   1600       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2443   2443       Phosphoserine.
FT                                {ECO:0000244|PubMed:17693683,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2556   2556       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES    2563   2563       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2567   2567       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   VAR_SEQ    2478   2493       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8922996}.
FT                                /FTId=VSP_040478.
FT   VARIANT    2093   2093       L -> H (in MRX99; does not affect
FT                                interaction with DCX; reduced subcellular
FT                                localization in the axonal growth cones;
FT                                dbSNP:rs587777317).
FT                                {ECO:0000269|PubMed:24607389}.
FT                                /FTId=VAR_071131.
FT   VARIANT    2157   2157       L -> I (in MRX99; unknown pathological
FT                                significance; does not affect interaction
FT                                with DCX; reduced subcellular
FT                                localization in the axonal growth cones;
FT                                dbSNP:rs587777319).
FT                                {ECO:0000269|PubMed:24607389}.
FT                                /FTId=VAR_071132.
FT   CONFLICT     25     25       Q -> L (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT    148    154       Missing (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT    468    468       L -> P (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT    476    476       W -> R (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT    506    506       K -> R (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT    621    621       A -> V (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT   1400   1400       L -> F (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT   1951   1951       L -> P (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
FT   CONFLICT   2330   2330       T -> P (in Ref. 1; CAA66942).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2570 AA;  292280 MW;  84CB979A405AA56F CRC64;
     MTATTRGSPV GGNDNQGQAP DGQSQPPLQQ NQTSSPDSSN ENSPATPPDE QGQGDAPPQL
     EDEEPAFPHT DLAKLDDMIN RPRWVVPVLP KGELEVLLEA AIDLSKKGLD VKSEACQRFF
     RDGLTISFTK ILTDEAVSGW KFEIHRCIIN NTHRLVELCV AKLSQDWFPL LELLAMALNP
     HCKFHIYNGT RPCESVSSSV QLPEDELFAR SPDPRSPKGW LVDLLNKFGT LNGFQILHDR
     FINGSALNVQ IIAALIKPFG QCYEFLTLHT VKKYFLPIIE MVPQFLENLT DEELKKEAKN
     EAKNDALSMI IKSLKNLASR VPGQEETVKN LEIFRLKMIL RLLQISSFNG KMNALNEVNK
     VISSVSYYTH RHGNPEEEEW LTAERMAEWI QQNNILSIVL RDSLHQPQYV EKLEKILRFV
     IKEKALTLQD LDNIWAAQAG KHEAIVKNVH DLLAKLAWDF SPEQLDHLFD CFKASWTNAS
     KKQREKLLEL IRRLAEDDKD GVMAHKVLNL LWNLAHSDDV PVDIMDLALS AHIKILDYSC
     SQDRDTQKIQ WIDRFIEELR TNDKWVIPAL KQIREICSLF GEAPQNLSQT QRSPHVFYRH
     DLINQLQHNH ALVTLVAENL ATYMESMRLY ARDHEDYDPQ TVRLGSRYSH VQEVQERLNF
     LRFLLKDGQL WLCAPQAKQI WKCLAENAVY LCDREACFKW YSKLMGDEPD LDPDINKDFF
     ESNVLQLDPS LLTENGMKCF ERFFKAVNCR EGKLVAKRRA YMMDDLELIG LDYLWRVVIQ
     SNDDIASRAI DLLKEIYTNL GPRLQVNQVV IHEDFIQSCF DRLKASYDTL CVLDGDKDSV
     NCARQEAVRM VRVLTVLREY INECDSDYHE ERTILPMSRA FRGKHLSFVV RFPNQGRQVD
     DLEVWSHTND TIGSVRRCIL NRIKANVAHT KIELFVGGEL IDPADDRKLI GQLNLKDKSL
     ITAKLTQISS NMPSSPDSSS DSSTGSPGNH GNHYSDGPNP EVESCLPGVI MSLHPRYISF
     LWQVADLGSS LNMPPLRDGA RVLMKLMPPD STTIEKLRAI CLDHAKLGES SLSPSLDSLF
     FGPSASQVLY LTEVVYALLM PAGAPLADDS SDFQFHFLKS GGLPLVLSML TRNNFLPNAD
     METRRGAYLN ALKIAKLLLT AIGYGHVRAV AEACQPGVEG VNPMTQINQV THDQAVVLQS
     ALQSIPNPSS ECMLRNVSVR LAQQISDEAS RYMPDICVIR AIQKIIWASG CGSLQLVFSP
     NEEITKIYEK TNAGNEPDLE DEQVCCEALE VMTLCFALIP TALDALSKEK AWQTFIIDLL
     LHCHSKTVRQ VAQEQFFLMC TRCCMGHRPL LFFITLLFTV LGSTARERAK HSGDYFTLLR
     HLLNYAYNSN INVPNAEVLL NNEIDWLKRI RDDVKRTGET GIEETILEGH LGVTKELLAF
     QTSEKKFHIG CEKGGANLIK ELIDDFIFPA SNVYLQYMRN GELPAEQAIP VCGSPPTINA
     GFELLVALAV GCVRNLKQIV DSLTEMYYIG TAITTCEALT EWEYLPPVGP RPPKGFVGLK
     NAGATCYMNS VIQQLYMIPS IRNGILAIEG TGSDVDDDMS GDEKQDNESN VDPRDDVFGY
     PQQFEDKPAL SKTEDRKEYN IGVLRHLQVI FGHLAASRLQ YYVPRGFWKQ FRLWGEPVNL
     REQHDALEFF NSLVDSLDEA LKALGHPAML SKVLGGSFAD QKICQGCPHR YECEESFTTL
     NVDIRNHQNL LDSLEQYVKG DLLEGANAYH CEKCNKKVDT VKRLLIKKLP PVLAIQLKRF
     DYDWERECAI KFNDYFEFPR ELDMEPYTVA GVAKLEGDNV NPESQLIQQS EQSESETAGS
     TKYRLVGVLV HSGQASGGHY YSYIIQRNGG DGERNRWYKF DDGDVTECKM DDDEEMKNQC
     FGGEYMGEVF DHMMKRMSYR RQKRWWNAYI LFYERMDTID QDDELIRYIS ELAITTRPHQ
     IIMPSAIERS VRKQNVQFMH NRMQYSMEYF QFMKKLLTCN GVYLNPPPGQ DHLLPEAEEI
     TMISIQLAAR FLFTTGFHTK KVVRGSASDW YDALCILLRH SKNVRFWFAH NVLFNVSNRF
     SEYLLECPSA EVRGAFAKLI VFIAHFSLQD GPCPSPFASP GPSSQAYDNL SLSDHLLRAV
     LNLLRREVSE HGRHLQQYFN LFVMYANLGV AEKTQLLKLS VPATFMLVSL DEGPGPPIKY
     QYAELGKLYS VVSQLIRCCN VSSRMQSSIN GNPPLPNPFG DPNLSQPIMP IQQNVADILF
     VRTSYVKKII EDCSNSEETV KLLRFCCWEN PQFSSTVLSE LLWQVAYSYT YELRPYLDLL
     LQILLIEDSW QTHRIHNALK GIPDDRDGLF DTIQRSKNHY QKRAYQCIKC MVALFSNCPV
     AYQILQGNGD LKRKWTWAVE WLGDELERRP YTGNPQYTYN NWSPPVQSNE TSNGYFLERS
     HSARMTLAKA CELCPEEVKK ATSVQQIEME ESKEPDDQDA PDEHESPPPE DAPLYPHSPG
     SQYQQNNHVH GQPYTGPAAH HMNNPQRTGQ RAQENYEGSE EVSPPQTKDQ
//
